Corrigendum to "A high-performance liquid chromatography-tandem mass spectrometry method for the analysis of lifirafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine, and its application in a clinical pharmacokinetic study" [J. Pharm. Biomed. Anal. 166 (2019) 20-29]
J Pharm Biomed Anal. 2020 Mar 20:181:112627.
doi: 10.1016/j.jpba.2019.04.047.
Epub 2019 Jun 27.
1 Clinical Pharmacology Research Center Phase I Unit, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100032, China; Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, Beijing 100032, China.
2 Clinical Pharmacology Research Center Phase I Unit, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100032, China; Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, Beijing 100032, China. Electronic address: liudongyang@vip.sina.com.
3 Clinical Pharmacology Research Center Phase I Unit, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100032, China; Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, Beijing 100032, China. Electronic address: hubei01_pumch@163.com.